Fatal fulminant hepatic failure due to cyproterone acetate

Dig Dis Sci. 1999 Jul;44(7):1362-3. doi: 10.1023/a:1026639432428.

Abstract

Cyproterone acetate is a normally well-tolerated drug that is used widely for the treatment of prostatic carcinoma. Liver toxicity due to its use is not well known. We describe two cases of fatal fulminant hepatitis related to the use of cyproterone acetate.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / adverse effects*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Chemical and Drug Induced Liver Injury / diagnosis*
  • Chemical and Drug Induced Liver Injury / pathology
  • Cyproterone Acetate / administration & dosage
  • Cyproterone Acetate / adverse effects*
  • Fatal Outcome
  • Hepatic Encephalopathy / chemically induced*
  • Hepatic Encephalopathy / diagnosis
  • Hepatic Encephalopathy / pathology
  • Humans
  • Liver / drug effects
  • Liver / pathology
  • Male
  • Neoplasm Staging
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology

Substances

  • Androgen Antagonists
  • Antineoplastic Agents
  • Cyproterone Acetate